Logo

Steve Chapman, Robert Schueren, Matthew Rabinowitz

Jan 02, 2019

Natera has appointed Steve Chapman to CEO. He will take over from Matthew Rabinowitz, who will serve as executive chairman, effective Jan. 2, 2019. Chapman was previously the company's chief operating officer and Robert Schueren will replace Chapman as Natera's COO, effective Jan. 7, 2019. Schueren was most recently CEO of IntegenX, which was acquired by Thermo Fisher Scientific. Previously, he was general manager of genomics at Agilent Technologies and has also held various roles at Genentech.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.